Eisai’s Bayesian Alzheimer’s Trial Aims For Quick Proof Of Concept With Fewer Subjects, Lower Cost
This article was originally published in PharmAsia News
Executive Summary
Eisai should get the first feedback from an adaptive Phase II trial of BAN2401 in Alzheimer’s patients with mild cognitive impairment in six or seven months, offering the first opportunity to adjust parameters testing dose response and the antibody’s disease-modifying potential or to stop the trial early for futility.
You may also be interested in...
Standards For Early Alzheimer’s Drugs Adapted, Not Loosened, FDA’s Katz Says
A draft guidance for development of drugs to treat early Alzheimer’s disease does not loosen agency standards, FDA’s neurology products chief asserts. Rather, it is an attempt to establish criteria tailored to the population.
Guidance For Drugs To Target Early Alzheimer’s Notes Lack Of Metrics, Biomarkers
FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease, before any noticeable dementia sets in, is sure to generate further discussion and comment on how best to identify and measure the disease and its progression.
Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 1 Of 2)
TOKYO - Swedish startup BioArctic Neuroscience CEO Pär Gellerfors wondered who was calling him at 8 a.m. one June morning back in 2003.